Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected?

[1] Degenhardt L(2019)Global patterns of opioid use and dependence: harms to populations, interventions, and future action Lancet 394 1560-1579

[2] Grebely J(2019)Prescription opioid analgesic use in France: trends and impact on morbidity-mortality Eur J Pain Lond Engl 23 124-134

[3] Stone J(2021)Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018 Eur Psychiatry 64 e47-44

[4] Hickman M(2022)A 13-year national monitoring study to assess narcotic prescriptions and indications (2007–2019) Drug Saf 45 37-122

[5] Vickerman P(2015)Comment identifier un signal en addictovigilance? Therapies 70 113-501

[6] Marshall BDL(2017)Dispositif pharmacoépidémiologique de surveillance des substances psychoactives: intérêts du programme national OPPIDUM du Réseau français d’addictovigilance Therapies 72 491-244

[7] Chenaf C(2013)Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France Eur Addict Res 19 235-475

[8] Kaboré JL(2016)Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area Fundam Clin Pharmacol 30 466-2348

[9] Delorme J(2019)Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients Br J Clin Pharmacol 86 2338-12

[10] Pereira B(2022)Oral morphine as an alternative substitution treatment for opioid use disorder, a rare but non-risk-free use Front Psychiatry 13 1-9

[1] Degenhardt L(2019)Global patterns of opioid use and dependence: harms to populations, interventions, and future action Lancet 394 1560-1579

[2] Grebely J(2019)Prescription opioid analgesic use in France: trends and impact on morbidity-mortality Eur J Pain Lond Engl 23 124-134

[3] Stone J(2021)Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018 Eur Psychiatry 64 e47-44

[4] Hickman M(2022)A 13-year national monitoring study to assess narcotic prescriptions and indications (2007–2019) Drug Saf 45 37-122

[5] Vickerman P(2015)Comment identifier un signal en addictovigilance? Therapies 70 113-501

[6] Marshall BDL(2017)Dispositif pharmacoépidémiologique de surveillance des substances psychoactives: intérêts du programme national OPPIDUM du Réseau français d’addictovigilance Therapies 72 491-244

[7] Chenaf C(2013)Slow-release oral morphine sulfate abuse: results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France Eur Addict Res 19 235-475

[8] Kaboré JL(2016)Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area Fundam Clin Pharmacol 30 466-2348

[9] Delorme J(2019)Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients Br J Clin Pharmacol 86 2338-12

[10] Pereira B(2022)Oral morphine as an alternative substitution treatment for opioid use disorder, a rare but non-risk-free use Front Psychiatry 13 1-9